Pharmacokinetics of cyclophosphamide administered alone or in combination with vindesin or cisplatin in 5 patients with bronchial adenocarcinoma.
The pharmacokinetics of cyclophosphamide (CPH) administered intravenously at doses between 200-400 mg alone or in combination with vindesin (VDS) or cisplatin (cisPt) were studied in 5 patients who had bronchial adenocarcinoma, with normal liver and kidney functions. The linearity and the reproducibility of CPH kinetics were confirmed and its pharmacokinetic parameters were found to be unaffected by simultaneous or sequential administration of either vindesin or cisplatin. Total clearance was 7.69 +/- 3.53 1.hr-1 for CPH administered alone and 6.76 +/- 1.63 1.hr-1 for CPH administered with vindesin. Biological half-life was 4.3 +/- 1.5 hr (CPH alone) and 5.1 +/- 2.2 hr (CPH + VDS).
Lartigue-Mattei
C
C
Groupe de Recherche en Biodynamique du Médicament Laboratoire de Chimie Analytique et de Spectrométrie de Masse.
Chabard
J L
JL
Touzet
C
C
Chollet
P
P
Plagne
R
R
Petit
J
J
Berger
J A
JA
D000230:Adenocarcinoma / Q000188:drug therapy*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000493:pharmacokinetics / Q000627:therapeutic use; D001984:Bronchial Neoplasms / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D006801:Humans; D014751:Vindesine / Q000008:administration & dosage
D003520:Cyclophosphamide; D002945:Cisplatin; D014751:Vindesine